In vivo pharmacokinetic study on curcumin-loaded nanostructured lipid carriers in rat based on UPLC-MS/MS analysis / 中草药

ABSTRACT

Objective: To study the pharmacokinetics of phosphatidylserine (PS)-containing curcumin-loaded nanostructured lipid carriers (Cur-mNLC), curcumin-loaded nanostructured lipid carriers without PS (Cur-NLC), and curcumin solutions in SD rats. Methods: Blood samples were collected from the orbit of rats at different periods of time after they were ip injected with Cur-solution, Cur-NLC, and Cur-mNLC at 10 mg/kg (corresponding to Cur), then Cur content in plasma was determined by UPLC-MS/MS, and the pharmacokinetic parameters were calculated by DAS software. Results: The pharmacokinetic parameters of Cur-solution, Cur-NLC, and Cur-mNLC were respectively calculated as follows Cmax (29.453±1.146), (20.045±0.818), (15.865±0.409) μg/L; MRT(0-∞) (18.196±1.456), (18.196±1.456), (89.252±12.049) h. The AUC(0-∞) of Cur-mNLC was 2.58 and 1.48 times larger than those of Cur-solution and Cur-NLC. Conclusion: The Cmax of Cur-NLC and Cur-mNLC are lower than that of Cur-solution, but the MRT(0-∞) of Cur-NLC and Cur-mNLC are longer than that of Cur-solution. Compared with Cur-NLC, Cur-mNLC has better sustained-release behaviors, which contributes to its superior bioavailability.